Pacific Biosciences of California (NASDAQ: PACB) shares rose 28.96% during regular trading on September 30, 2026, moving from $1.83 at the prior close to $2.36. The stock saw extraordinary volume of more than 61 million shares trade, compared to its average daily volume of roughly 4.7 million shares.

What happened

PACB was the highest-volume mover during Tuesday's regular session, with shares staging a sharp intraday rally. The company has been working through a leadership transition after appointing Mark Van Oene as President and Chief Executive Officer on August 5, 2026, succeeding Christian O. Henry. PacBio also participated in the Morgan Stanley 24th Annual Global Healthcare Conference in September, where executives discussed the company's clinical growth strategy.

Why the stock moved

The move appeared to reflect renewed investor interest in the sequencing company rather than a single named catalyst. Trading volume hit more than 13 times the average daily volume, suggesting short-covering and speculative buying. PacBio has been working to drive adoption of its HiFi sequencing technology for clinical applications while targeting $40 million in cost savings. MarketBeat reported on September 20 that PacBio was targeting clinical growth alongside its cost-reduction efforts. The company's Q2 2026 earnings on August 5 showed a revenue miss and widened loss, leading to a reduced 2026 sales outlook.

The numbers

Metric | Value

---|---

Session change | +28.96% Last price | $2.36 Prior close | $1.83 Session volume | 61,012,801 Avg daily volume | ~4,660,230 Market cap | $733 million Float | 303,830,571

What to watch

Investors should monitor PacBio's progress on its clinical adoption strategy, particularly for its HiFi sequencing platform. The company is targeting 2028 cash-flow positivity and has identified $40 million in potential savings as it works through its SPRQ-Nx platform transition. Watch for any updates on the timeline for reaching cash-flow positive operations and whether the clinical sequencing segment can drive revenue growth. The next earnings report will be key for assessing whether the company can close the gap between its current trajectory and its 2026 guidance.

For more details on Pacific Biosciences, including real-time quotes, SEC filings, and the latest news, visit the PACB quote page on Vantafin.